FOLH1 and prostate carcinoma: The UniCAR system is also being tested in solid tumors: the NCT04633148 dose-escalating phase I trial is currently recruiting patients with prostate-specific membrane antigen (PSMA)+ prostate cancer to evaluate the safety and efficacy of the PSMA-directed UniCAR platform AVC-102 (also developed by AvenCell Therapeutics) (34).